MIT Technology Review Subscribe

Finding Early Signs of Mad-Cow Disease

A comprehensive study of gene-expression changes could lead to new diagnostic tests.

Researchers have made a list of blood proteins that act as early indicators of a group of diseases including bovine spongiform encephalopathy (BSE), also known as mad-cow disease. Their results could lead to commercial early warning tests for the disease in farm animals. The methods used for the study–one of the most comprehensive analyses of the gene expression characteristic of a disease–are now being applied to other diseases and could lead to early diagnosis tests for other neurological diseases such as Alzheimer’s.

Disease damage: This microscopy image shows brain tissue damaged by Creutzfeldt-Jakob disease.

The human form of BSE, a fatal degenerative neurological disorder called Creutzfeldt-Jakob disease, can be contracted by eating meat contaminated with infectious agents called prions. Prions are proteins that cause other proteins to misfold, particularly in the brain and other neural tissue. In the first stages of the disease, prions replicate and accumulate in the brain. This is followed by abnormal activation of supportive cells, the degeneration of neural connections, and finally brain-cell death. By the time the disease can be diagnosed, these processes are already well under way.

Advertisement

In order to illuminate these ordinarily invisible processes, the researchers infected mice with prions and followed changes in the expression of every single gene in their brains at 10 points throughout the course of the disease. This global approach generated about 30 million data points. In order to separate signal from noise–that is, to find genes that were truly a significant part of the disease process–the researchers developed new statistical methods for looking at how the genes interact with one another in interrelated groups. Of an initialgroup of 7,400 implicated genes, they winnowed the number down to about 300 that are “at the heart of prion response,” says Leroy Hood, president and co-founder of the Institute for Systems Biology in Seattle, WA. Hood has pioneered this type of analysis, which he calls systems biology, over the past decade and led the new research with George Carlson, director of the McLaughlin Research Institute in Great Falls, MT.

This story is only available to subscribers.

Don’t settle for half the story.
Get paywall-free access to technology news for the here and now.

Subscribe now Already a subscriber? Sign in
You’ve read all your free stories.

MIT Technology Review provides an intelligent and independent filter for the flood of information about technology.

Subscribe now Already a subscriber? Sign in

The researchers further studied the 300 genes to find those that are known to code for proteins that are secreted into the blood. They discovered that some of those proteins could be found in the blood of infected mice 8 to 10 weeks before they started showing any symptoms. These results are described today in the journal Molecular Systems Biology. Hood says that the researchers are now looking into developing commercial tests for the human and bovine forms of prion disease, based on the blood biomarkers they have uncovered. Cows and humans have almost identical blood proteins to those uncovered in the mouse study.

“This global analysis let us pick up lots of features that were previously unknown,” says Hood. Only 200 of the implicated genes have a role in the disease process that is understood. So further study of the remaining 100 could lead to new insights into how prions cause disease. And all of the genes provide therapeutic targets for drug developers to investigate.

Hood now hopes to develop blood tests for other difficult-to-diagnose brain diseases. Having proven their analytical method in prion diseases, Hood says the group will apply it to mouse models of other degenerative diseases of the nervous system including Alzheimer’s and Huntington’s. Like Creutzfeldt-Jakob, “these diseases are difficult to diagnose in their early stages,” says Hood. The earlier the diagnosis, the better the outcomes are likely to be.

This is your last free story.
Sign in Subscribe now

Your daily newsletter about what’s up in emerging technology from MIT Technology Review.

Please, enter a valid email.
Privacy Policy
Submitting...
There was an error submitting the request.
Thanks for signing up!

Our most popular stories

Advertisement